SynthesisThe Cochrane database of systematic reviews2012
Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.
Synthesis in The Cochrane database of systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 8 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- A Systematic Review of Management of Cramping Pain in Patients with Amyotrophic Lateral Sclerosis.European neurology · 2025Pooled it
- Efficacy of pain management strategies in adults with Amyotrophic Lateral Sclerosis (ALS): A Systematic Review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.JAMA network open · 2024Pooled it
- Non-drug therapies for the secondary prevention of lower limb muscle cramps.The Cochrane database of systematic reviews · 2021Pooled it
- Interventions for leg cramps in pregnancy.The Cochrane database of systematic reviews · 2020Pooled it
- Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2017Pooled it
- Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2017Pooled it
- Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.The Cochrane database of systematic reviews · 2013Pooled it
- Trial
- A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.Neurology · 2016Trial
- Metabolomic analyses of amyotrophic lateral sclerosis, muscle cramps, and TJ-68 treatment.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Pan-Asian consortium for treatment and research in ALS (PACTALS) guidelines for management of amyotrophic lateral sclerosis.The Lancet regional health. Western Pacific · 2025Review
- Progressive Bulbar Palsy (PBP) or Bulbar Onset MND: "A Case Report".Journal of pharmacy & bioallied sciences · 2025Article
- Non-motor symptoms in patients with amyotrophic lateral sclerosis: current state and future directions.Journal of neurology · 2024Review
- Amyotrophic Lateral Sclerosis and Pain: A Narrative Review from Pain Assessment to Therapy.Behavioural neurology · 2024Review
- Article
- Herbal medicine and acupuncture relieved progressive bulbar palsy for more than 3 years: A case report.Medicine · 2022Article
- Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis.Muscle & nerve · 2022Article
- Pain in amyotrophic lateral sclerosis: a narrative review.Journal of Yeungnam medical science · 2022Article
- Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.Drug safety · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCramps are painful, involuntary muscle contractions. They commonly affect people with amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) at all stages of the disease. To date, the treatment of muscle cramps in ALS has been largely empirical without any evidence from randomised controlled trials.
objectivesTo systematically assess the effect of interventions on muscle cramps as a primary or secondary endpoint or adverse event in people with ALS/MND. SEARCH
methodsWe searched the Cochrane Neuromuscular Disease Group Specialized Register (14 February 2011), the Cochrane Central Register of Controlled Trials (Issue 1, 2011 in The Cochrane Library), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011) and reference lists of articles searched using the terms motor neuron disease, motor neurone disease, motoneuron disease or amyotrophic lateral sclerosis. We contacted authors of trials for further information. SELECTION CRITERIA: We included all randomised and quasi-randomised trials of oral medications in people with ALS which assessed cramps as a primary or secondary outcome measure or as an adverse event. We also included trials using subcutaneous or intravenous medications or physical therapy. DATA COLLECTION AND ANALYSIS: All authors applied the selection criteria and assessed study quality independently, and all authors performed independent data extraction. MAIN
resultsTwenty studies including 4789 participants were identified. Only one trial, of tetrahydrocannabinol (THC), assessed cramps as the primary endpoint. Thirteen studies assessed cramps as a secondary endpoint. The medications comprised vitamin E, baclofen, riluzole, L-threonine, xaliproden, indinavir, and memantine. Six studies assessed cramps as an adverse event. The medications comprised creatine, gabapentin, dextromethorphan, quinidine, and lithium. In all 20 studies no favourable effect for the treatment of cramps in ALS/MND could be demonstrated, but many studies were underpowered to draw a definite conclusion. A meta-analysis of two small studies showed a statistically nonsignificant result for the amino acid L-threonine for the treatment of cramps in ALS/MND. No study was identified using physical therapy as a therapeutic intervention for cramps. AUTHORS'
conclusionsThere is no evidence to support the use of any intervention for muscle cramps in ALS/MND. More and larger randomised controlled trials evaluating treatments for muscle cramps in ALS/MND are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.